News Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-23 pm EDT			5-day change	1st Jan Change
2.715 ^USD	-3.37%		-5.07%	-4.40%

Feb. 14	Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Feb. 14	Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024	Feb. 14
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	Feb. 14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	Jan. 24	AQ
Transcript : Aytu BioPharma, Inc., Q1 2024 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M	Nov. 14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	23-10-26	MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	23-10-26	CI
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer	23-10-06	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M	23-09-27	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-09-27	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Aytu BioPharma to Present at LD Micro Main Event XVI Conference	23-09-14	AQ
Maxim Starts Aytu BioPharma at Buy With $5 Price Target	23-08-09	MT
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority	23-08-01	AQ
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	23-07-31	CI
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	23-07-10	CI
AYTU BIOPHARMA, INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	23-06-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Summary

Filters